Contact
searchSearch
HMP Global
Teaching Collection

The Stenotic Aortic Valve (Part I)

Morton J. Kern, MD, MSCAI, FACC, FAHA
06/18/2020

Related Content

TAVR
TAVR Use Increased Nearly Ninefold Among Patients Under 70 in Health System Analysis
11/04/2026
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among...
11/04/2026
Cath Lab Digest
TAVR for Moderate AS
PROGRESS Trial: TAVR Improves Outcomes for Patients with Moderate Aortic Stenosis and At-Risk Features
11/02/2026
In a randomized trial of patients with moderate AS and at least one at-risk feature, those who underwent earlier TAVR had improved outcomes at two years than those managed with clinical surveillance.
In a randomized trial of patients with moderate AS and at least one at-risk feature, those who underwent earlier TAVR had improved outcomes at two years than those managed with clinical surveillance.
In a randomized trial of...
11/02/2026
Cath Lab Digest
Aortic Stenosis: AI
TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI’s AVC Solution
11/02/2026
Nanox.AI's Investigational AVC Solution Demonstrated 98.3% Sensitivity and 96.6% Specificity in Evaluable CT Scans. Findings Highlight the Potential of AI to Identify Previously Unreported Aortic Valve Calcification Using Existing Routine CT...
Nanox.AI's Investigational AVC Solution Demonstrated 98.3% Sensitivity and 96.6% Specificity in Evaluable CT Scans. Findings Highlight the Potential of AI to Identify Previously Unreported Aortic Valve Calcification Using Existing Routine CT...
Nanox.AI's Investigational AVC...
11/02/2026
Cath Lab Digest
moderate AS: clinical trial
Medtronic Presents Evolut EXPAND TAVR II Trial Design and Baseline Characteristics of Patients With Moderate Aortic Stenosis at TCT 2026
10/31/2026
Featured clinical science presentation highlights global randomized trial investigating TAVR intervention alongside guideline-directed medical therapy.
Featured clinical science presentation highlights global randomized trial investigating TAVR intervention alongside guideline-directed medical therapy.
Featured clinical science...
10/31/2026
Cath Lab Digest

Subscriber

Cath Lab Digest Newsletter

Clinical & Industry News

FFR CT Analysis
CT-Guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients
11/04/2026
Late-Breaking P4 study shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions. NAVIGATE-PCI shows Heartflow PCI Navigator drove...
Late-Breaking P4 study shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions. NAVIGATE-PCI shows Heartflow PCI Navigator drove...
Late-Breaking P4 study shows CT...
11/04/2026
Cath Lab Digest
Women and PE
SYMPHONY-PE IDE: First-in-Field Analysis Provides Encouraging Safety Findings for Women with Pulmonary Embolism
11/04/2026
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Sub-analysis presented at TCT...
11/04/2026
Cath Lab Digest
Renal Denervation
TCT26: Renal Denervation with Medtronic Symplicity Shows Significant Blood Pressure Drops in SPYRAL AFFIRM Real-World Study
11/04/2026
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Nearly nine out of 10 patients...
11/04/2026
Cath Lab Digest
TAVR
TAVR Use Increased Nearly Ninefold Among Patients Under 70 in Health System Analysis
11/04/2026
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among...
11/04/2026
Cath Lab Digest
Vertex Catheter (Jupiter Endovascular)
Pulmonary Embolism
New SPIRARE II Data at TCT 2026 Show Restoring Normal Pulmonary Pressure Using Vertex System Tracked with Right Heart Recovery in Pulmonary Embolism
11/03/2026
Post-hoc analysis presented by Dr. Sripal Bangalore also found reaching lower lobes of lungs was associated with greater hemodynamic restoration without added safety concerns.
Post-hoc analysis presented by Dr. Sripal Bangalore also found reaching lower lobes of lungs was associated with greater hemodynamic restoration without added safety concerns.
Post-hoc analysis presented by...
11/03/2026
Cath Lab Digest
renal denervation
Paradise uRDN System Demonstrates 19.5 mmHg Blood Pressure Reduction at 12 Months, with Durability Through 4 Years
11/03/2026
Seven abstracts sponsored by Recor Medical presented at TCT 2026 highlight expanding clinical evidence for ultrasound renal denervation.
Seven abstracts sponsored by Recor Medical presented at TCT 2026 highlight expanding clinical evidence for ultrasound renal denervation.
Seven abstracts sponsored by...
11/03/2026
Cath Lab Digest
transcatheter heart valves
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
11/03/2026
Anteris Technologies Global Corp. announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492...
Anteris Technologies Global Corp. announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492...
Anteris Technologies Global...
11/03/2026
Cath Lab Digest
radiation safety
Lead-Free Shielding System Associated with Low Operator Radiation Exposure During Endovascular Procedures
11/02/2026
Multicenter study reports low operator radiation exposure across 95 sites using an alternative to traditional lead-apron protection.
Multicenter study reports low operator radiation exposure across 95 sites using an alternative to traditional lead-apron protection.
Multicenter study reports low...
11/02/2026
Cath Lab Digest
R-Star system (Robocath)
Robotic PCI
First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT
11/02/2026
The findings support a favorable performance profile for the system, with 100% clinical success rate and no device-related complications.
The findings support a favorable performance profile for the system, with 100% clinical success rate and no device-related complications.
The findings support a favorable...
11/02/2026
Cath Lab Digest
Left Atrial Appendage Occlusion
SIMPLAAFY Study: Less Intensive Antithrombotic Strategies Met Noninferiority Compared with DAPT After Left Atrial Appendage Closure
11/02/2026
New findings from the randomized SIMPLAAFY trial suggest that less intensive antithrombotic therapy following left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro LAAC Device can reduce the risk of clinically-relevant bleeding...
New findings from the randomized SIMPLAAFY trial suggest that less intensive antithrombotic therapy following left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro LAAC Device can reduce the risk of clinically-relevant bleeding...
New findings from the randomized...
11/02/2026
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use